Cipla Performance
- Today's Low
- ₹1,452
- Today's High
- ₹1,471
- 52 Week Low
- ₹1,166
- 52 Week High
- ₹1,673
- Open Price₹1,452
- Previous Close₹1,456
- Volume1,261,674
- 50 DMA₹1,384.18
- 100 DMA₹1,374.74
- 200 DMA₹1,399.54
Cipla Chart
Investment Returns
- Over 1 Month + 6.04%
- Over 3 Month + 22.29%
- Over 6 Month -3.53%
- Over 1 Year -3.35%
Smart Investing Starts Here Start SIP with Cipla for Steady Growth!
Cipla Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.
- P/E Ratio
- 30.4
- PEG Ratio
- -1.1
- Market Cap Cr
- 117,800
- P/B Ratio
- 3.4
- Average True Range
- 28.77
- EPS
- 47.12
- Dividend Yield
- 0.9
- MACD Signal
- 18.27
- RSI
- 66.8
- MFI
- 74.42
Latest Stock News Updates
Cipla's stock surged following Citi's 'Buy' rating and a 90-day Positive Catalyst Watch. The brokerage anticipates growth from potential US approvals like gFlovent and gVentolin, alongside a rebound in its US business. Domestically, Cipla's performance remains strong, supported by its respiratory portfolio. Citi sees earnings bottoming out and highlights attractive valuations for the Indian market.
- Economic Times
- 1 week 5 days ago
Homegrown pharma major Cipla Ltd on Tuesday announced the appointment of Shivam Puri as the CEO of its 'One India Business' with effect from July 1, 2026. Puri, currently Managing Director and CEO of Cipla Health Ltd, a wholly-owned subsidiary of the company, has over 23 years of leadership experience across both FMCG and healthcare sectors. He brings strong commercial acumen and consumer-centric expertise, Cipla said in a regulatory filing. He took over as MD and CEO of Cipla Health in 2019, and under his leadership, the company rapidly expanded its portfolio and strengthened its presence across key consumer categories, such as smoking cessation, pain care, cough and cold, skin care, hair care and nutrition, among others, Cipla said. Before joining Cipla Health in 2019, Puri held senior leadership roles at Hindustan Unilever, Jubilant FoodWorks and ITC Ltd, the filing said.
- Business Standard
- 2 weeks 4 days ago
The drugmaker has approved investments of over Rs 4,000 crore in the past two years to expand respiratory APIs, oncology ingredients, inhalation products and global manufacturing capacity
- Business Standard
- 2 weeks 4 days ago
Cipla Financials
Cipla Technicals
EMA & SMA
- Bearish Moving Average 0
- Bullish Moving Average 16
- 20 Day
- ₹1,418.70
- 50 Day
- ₹1,384.20
- 100 Day
- ₹1,374.70
- 200 Day
- ₹1,399.50
Resistance and Support
- R3 1,487.80
- R2 1,479.40
- R1 1,468.80
- S1 1,449.80
- S2 1,441.40
- S3 1,430.80
Cipla Corporate Actions - Bonus, Splits, Dividends
Cipla F&O
About Cipla
Cipla Ltd. is a pharmaceutical company in India with a strong global presence. With operations in 80 countries and 47 manufacturing facilities, it sells 1500 products in the market. The largest market of Cipla Ltd. is India, followed by Africa and North America.
The product profile of Cipla Ltd. ranges from drugs in the respiratory, pediatric asthma, nebulisation, anti-retroviral, urology, cardiology, anti-infective, CNS, and several other illnesses and disorders. Cipla's business is divided into three units - Generics and Branded Generics, Specialty and Consumer Health.
The Generics and Branded Generics unit contributes around 19% of the pharmaceutical revenues in India. The division has 4,000+ partners covering the entire country and is constantly seeking to expand the product portfolio.
The Specialty unit focuses on speciality medicines in respiratory, CNS and critical care. This unit's operations are run under Cipla Technologies LLC (CipTec) and have its headquarters in San Diego, California.
The Consumer Health Segment focuses on simplifying healthcare and offering simple and over-the-counter solutions to the consumers. A few brands under this business unit are Nicotex, ActivKids ImmunoBoosters, Cofsils, and UnoBiotics.
Cipla was founded in 1935 in Mumbai as Chemical Industrial & Pharmaceutical Laboratories Ltd. by Khwaja Abdul Hamied. The name of the company was changed to Cipla in 1984. It received a major boost in 1985 when the US FDA approved its bulk drug facility. Cipla went on to launch the world's first oral iron chelator in 1995.
The company acquired the South African company Cipla-Medproin in 2013 and entered digital therapeutics by partnering with Wellthy Therapeutics in India and Brandmed in South Africa in 2019.
In September 2021, Cipla Ltd. subscribed to 5% equity shares (on a fully diluted basis) of Swasth Digital Health Foundation. It is a not-for-profit organisation focused on building digital healthcare infrastructure.
Shareholding Pattern
A total of 230 mutual funds invest in Cipla Ltd., with a total holding of 13.91%. The number of FIIs and FPIs that have invested in it is 786, and their total holding amount to 26.64. These figures are as of March 2022.
The top mutual funds that have invested in Cipla Ltd. are SBI ETF Nifty 50, Baroda BNP Paribas Balanced Advantage Fund Regular Growth, Mirae Asset Healthcare Fund Regular Growth, Franklin India Bluechip Fund-Growth and UTI Nifty ETF.
View More- NSE Symbol
- CIPLA
- BSE Symbol
- 500087
- Managing Director & Global CEO
- Mr. Umang Vohra
- ISIN
- INE059A01026
Similar Stocks to Cipla
Popular Stocks
Cipla FAQs
Cipla share price is ₹1,458 As on 05 July, 2026 | 09:25
The Market Cap of Cipla is ₹117800 Cr As on 05 July, 2026 | 09:25
The P/E ratio of Cipla is 30.4 As on 05 July, 2026 | 09:25
The PB ratio of Cipla is 3.4 As on 05 July, 2026 | 09:25
Cipla may be the correct pick right now for investors searching for value buys of quality stocks with a longer time horizon. Cipla comes with a HOLD recommendation from the analyst. Cipla has a trailing 12-month operating revenue of INR 20,799.29 crore. Annual revenue growth of 11% is strong, the pre-tax margin of 17% is excellent, and ROE of 13% is excellent. The company has a debt-to-equity ratio of 7%, which indicates a stable balance sheet. Institutional holding has gone up in the last reported quarter is a positive sign.
Cipla Limited, headquartered in Mumbai, India, is an Indian multinational pharmaceutical corporation. Cipla primarily produces drugs for the treatment of respiratory, cardiovascular, arthritis, diabetes, weight loss, and depression, as well as other medical disorders.
Umang Vohra has been the CEO of Cipla since 1 September 2016.
Cipla's stock price CAGR over ten years is 11%, five years is 10%, three years is 20%, and one year is 22% percent.
You can easily buy the shares of Grasim Industries Ltd. by registering at 5Paisa and setting up a Demat Account in your name to start trading.
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.